🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Germany
Clinical trial register · European Union · CTIS

Clinical Trials in Germany

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12445 total CTIS records — a stated recency window, not the full historical archive. Synced 20 Sep 2026, 03:17 UTC
2500
Shown in this register
most recently authorised
12,445
Total on CTIS
full historical archive
745
Phase III
within the shown window
Top member states
Spain 1023 France 890 Germany 861 Italy 742 Poland 581 Netherlands 524
Narrow the registerReset
Phase
Phase I 558 Phase I/II 214 Phase II 726 Phase III 745 Phase IV 257
Lead sponsor
AstraZeneca AB 60 Assistance Publique Hopitaux De Paris 49 Merck Sharp & Dohme LLC 48 Pfizer Inc. 45 Novo Nordisk A/S 42
Member state
Spain 1023 France 890 Germany 861 Italy 742 Poland 581 Netherlands 524 Belgium 426 Czechia 327
All 28 states
142 of 2500 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase I
A trial to learn how well different doses of andexanet alfa work and how they affect blood clotting throughout the body in healthy adults who have taken an FXa inhibitor
2025-522513-30-00Healthy Volunteers
AstraZeneca AB
Not possible to specify
Germany
09/01/2026
Phase I
A study to compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 with US-Dupixent®, and EU-Dupixent® in Healthy Adult Participants.
2025-523115-11-00Phase I study in healthy participants. Intended indication:…
Chong Kun Dang Pharmaceutical Corp.
Immune System Diseases
Germany
09/01/2026
Phase I
Phase Ib Dose-Ranging Study of the Safety, PK, PD & Efficacy of the Activin Signaling Inhibitor HS235 vs placebo added to background therapy in PAH (SEASIDE)
2025-523010-89-00Pulmonary arterial hypertension
35Pharma Inc.
Cardiovascular Diseases
Hungary, Spain, Poland, Germany, Czechia
23/12/2025
Phase I
A clinical trial investigating the safety and biological activity of the antibody BNT351 in adults living without and with HIV
2025-523846-29-00HIV-1 infection
BioNTech SE
Virus Diseases
Germany
22/12/2025
Phase I
A study in healthy men to test how itraconazole influences the amount of BI 764198 in the blood
2025-523135-19-00Healthy volunteer trial
Boehringer Ingelheim International GmbH
Not possible to specify
Germany
16/12/2025
Phase I
A Phase 1b, Prospective, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Safety and Tolerability of Multiple Oral Doses of IRL757 in Participants with Parkinson’s Disease and Apathy
2025-523612-37-00Parkinson's Disease and Apathy
Integrative Research Laboratories Sweden AB
Nervous System Diseases
Bulgaria, Poland, Spain, Germany
12/12/2025
Phase I
A phase 1 glucose clamp trial investigating the bioequivalence of CVC-001 cartridge vs U.S.-Licensed Lantus® in healthy male volunteers
2024-516472-15-00Type 1 diabetes mellitus (healthy participants)
Civica Inc.
Nutritional and Metabolic Diseases
Germany
12/12/2025
Phase I
A Double-blind, Placebo-controlled, Multiple-Dose, 2-Period Crossover Study to Evaluate the Effect of Steady-state AZD6793 on the Steady-state Pharmacokinetics/Pharmacodynamics of Metformin in Participants with Type 2 Diabetes Mellitus
2025-522551-25-00Type 2 Diabetes Mellitus
AstraZeneca AB
Nutritional and Metabolic Diseases
Germany
27/11/2025
Phase I
A Phase 1B, Open-Label Study of Mirdametinib in Infants and Toddlers with Neurofibromatosis Type 1 associated Plexiform Neurofibromas
2025-522000-24-00Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofi…
Springworks Therapeutics Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Spain, Germany
26/11/2025
Phase I
A Phase 1b open label pilot study of CLN-978 for the treatment of moderate to severe systemic lupus erythematosus (SLE)
2024-518780-36-00Systemic Lupus Erythematosus
Cullinan Therapeutics Inc.
Musculoskeletal Diseases
Bulgaria, Romania, France, Germany, Spain, Poland
25/11/2025
Phase I
CLonE-specific CAR T-Cell therapy in relapsed or refractory AL amyloidosis - a single-center Phase I trial (CLEAR AL)
2025-520790-39-00relapsed or refractory AL amyloidosis
Universitaetsklinikum Heidelberg AöR
Immune System Diseases
Germany
25/11/2025
Phase I
A research study of a new medicine NNC0363-1063 in participants with type 1 diabetes
2025-521593-33-00Diabetes type 1
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Germany
20/11/2025
Phase I
Pharmacokinetics, pharmacodynamics, safety, and tolerability of an acetonic milk thistle extract, standardized to silymarin, in subjects with MASLD
2025-522423-95-00chronic liver disease
Bionorica SE
Nutritional and Metabolic Diseases
Germany
17/11/2025
Phase I
Investigating the pharmacokinetics of petrelintide using different drug product concentrations in participants with a BMI ≥27.0 kg/m2
2025-520598-38-00Weight reduction
Zealand Pharma A/S
Nutritional and Metabolic Diseases
Germany
17/11/2025
Phase I
Open label study to investigate patch adhesion of an Esflurbiprofen-containing patch in healthy volunteers
2025-523577-42-00Patch adhesion trial with healthy subjects, therapeutical i…
Teikoku Seiyaku Co. Ltd.
Musculoskeletal Diseases
Germany
13/11/2025
Phase I
A single dose, randomized, double-blind 2-arm parallel-group study to compare the pharmacokinetics, immunogenicity, and safety for PB016 versus US-licensed Entyvio® after subcutaneous administration in healthy participants
2025-522534-31-00Not applicable, healthy volunteers
Polpharma Biologics S.A.
Not possible to specify
Germany
13/11/2025
Phase I
A first study in humans testing the safety and effects of KUP-101A in patients with certain advanced solid cancers
2025-522402-21-00Advanced solid tumors (cutaneous melanoma, mucosal melanoma…
Kupando GmbH
Neoplasms
Germany
12/11/2025
Phase I
A study to learn how safe nurandociguat is when taken with sildenafil in men with arterial hypertension.
2025-522336-14-00Chronic Kidney Disease, Arterial hypertension
Bayer AG
Cardiovascular Diseases
Germany
12/11/2025
Phase I
A first-in-human study to learn about how safe BAY 3620122 is, how much of it gets absorbed in the blood, and how it affects the body of healthy participants
2025-523301-15-00Vasodilatory shock
Bayer AG
Cardiovascular Diseases
Germany
11/11/2025
Phase I
A study in healthy people to test whether BI 764198 influences the amount of metformin in the body
2025-522432-14-00Healthy volunteer trial
Boehringer Ingelheim International GmbH
Not possible to specify
Germany
05/11/2025
Phase I
AMG 410 Alone and in Combination with other agents in Participants with KRAS Altered Advanced or Metastatic Solid Tumors
2025-521707-48-00KRAS Altered Advanced or Metastatic Solid Tumors
Amgen Inc.
Neoplasms
France, Netherlands, Germany, Denmark, Spain, Italy, Belgium
28/10/2025
Phase I
A research study of a new medicine, NNC9733-0001, in healthy participants and participants with type 2 diabetes
2024-519382-22-00Healthy Participants and Participants with type 2 diabetes
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Germany
24/10/2025
Phase I
A Trial to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Insulin GZR33 Compared with Insulin Degludec at steady state in participants with Type 1 Diabetes
2025-523052-32-00Type 1 diabetes Mellitus
Gan & Lee Pharmaceuticals USA Corp.
Hormonal diseases
Germany
15/10/2025
Phase I
Assessment of the safety and effects on the body of investigational products when used on psoriatic skin
2025-522446-51-00Plaque psoriasis
Bacoba AG
Immune System Diseases
Germany
09/10/2025
Phase I
A multi-part, adaptive, Phase 1, first time in human study in healthy participants and participants with atopic dermatitis (AD) to assess the safety, tolerability, pharmacokinetics (PK) of single ascending (SAD), multiple ascending doses (MAD) and selected dose of SYX-5219 (AD Participants)
2025-522216-17-00Atopic Dermatitis
Sitryx Therapeutics Limited
Skin and Connective Tissue Diseases
Germany, Bulgaria, Ireland, Denmark
09/10/2025
Rows per page Showing 101–125 of 142
Previous 3 4 5 6 Next
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 20 September 2026. https://priyalifescience.com/clinical-trials-europe/country/germany

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.